ASP4132

Astellas Pharma Global Development, Inc. · Phase 1 active Small molecule

At a glance

Generic name	ASP4132
Sponsor	Astellas Pharma Global Development, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASP4132 CI brief — competitive landscape report
ASP4132 updates RSS · CI watch RSS
Astellas Pharma Global Development, Inc. portfolio CI